Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American Home Products

Executive Summary

Workers at AHP plants in Elkhart, Ind. and Great Valley, Pa. file a $1 bil. class action RICO anti-racketering civil suit against the firm on Feb. 26 in San Juan, Puerto Rico federal court. The suit alleges that AHP illegally "destroyed" more than 1,400 mainland jobs in favor of plants in Puerto Rico. The documents note that in 1990, AHP reported federal tax savings of $84.1 mil. under Section 936 rules. AHP's two Puerto Rico plants "with less than 2% of AHP's worldwide workforce, today account for more than 35% of the company's net income," the suit alleges. An earlier suit filed against AHP in January 1991 by the Chemical and Atomic Workers International Union in connection with the Elkhart plant shutdown ("The Pink Sheet" Jan. 28, 1991, T&G-10), goes to trial March 30.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel